Fishnet NewMedia

Ultragenyx In-Licenses Therapeutic Program for Rare Genetic Disease Mucopolysaccharidosis Type 7 from St. Louis University

Thu, 05 Jan 2012 05:13:00 GMT

Ultragenyx Pharmaceutical, Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced it has in-licensed an enzyme replacement therapy program from St. Louis University to treat mucopolysaccharidosis type 7 (MPS 7). The in-licensed program is a treatment for an ultra-rare genetic, metabolic disorder that results from the deficiency of the beta-glucuronidase (GUS) enzyme. Also known as Sly syndrome, the disorder was first identified in 1973 by William S. Sly, MD, a world-renowned researcher in inherited diseases, who is currently Professor and Chairman Emeritus, Department of Biochemistry and Molecular Biology, at St. Louis University School of Medicine. Dr. Sly will collaborate with Ultragenyx on the MPS 7 development program.

Cornerstone Therapeutics Acquires Cardiokine

Wed, 04 Jan 2012 05:13:00 GMT

Cornerstone Therapeutics (NASDAQ: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products for the hospital and respiratory markets, today announced that it has acquired Cardiokine Inc., a specialty pharmaceutical company focused on developing hospital products for cardiovascular indications. The merger was effective Dec. 30, 2011.

The New England Journal of Medicine Publishes Study Showing LigoCyte�s Norovirus Vaccine Demonstrates Protection Against Illness

Thu, 08 Dec 2011 05:13:00 GMT

LigoCyte Pharmaceuticals, Inc. announced today that its experimental vaccine provided significant protection against norovirus infection and related gastrointestinal illness collectively known as acute gastroenteritis (AGE). Norovirus infection, sometimes referred to as &amp;amp;amp;quot;the stomach flu&amp;amp;amp;quot; is one of the most common causes of severe nausea, vomiting, abdominal cramps and diarrhea afflicting 21 million Americans annually and is an important contributor to gastrointestinal disease worldwide. This was the first time a vaccine has demonstrated protection against norovirus.